Table 6 Annual eGFR change (ΔeGFR) before and after hypouricemic treatment
From: Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease
CKD stage | PreTx (1Â yr) | Initiation of Tx | PostTx (1Â yr) | p-value* |
|---|---|---|---|---|
Total (n = 53) | ||||
 sUA (mg/dL) | 7.88 ± 1.09 | 8.70 ± 0.78 | 6.22 ± 1.40 |  |
 eGFR (mL/min/1.73 m2) | 53.2 ± 20.3 | 47.9 ± 20.3 | 48.1 ± 22.9 |  |
 ΔeGFR (mL/min/1.73 m2/yr) | −5.3 ± 8.2 |  | 0.2 ± 6.2 | 0.001 |
Stage 1-3a (n = 32) | ||||
 sUA (mg/dL) | 8.06 ± 1.15 | 8.66 ± 0.90 | 5.70 ± 1.41 |  |
 eGFR (mL/min/1.73 m2) | 64.8 ± 16.3 | 60.3 ± 16.1 | 62.6 ± 16.4 |  |
 ΔeGFR (mL/min/1.73 m2/yr) | −4.5 ± 9.4 |  | 2.3 ± 5.7 | 0.001 |
Stage 3b-4 (n = 21) | ||||
 sUA (mg/dL) | 7.62 ± 0.97 | 8.77 ± 0.59 | 7.03 ± 0.94 |  |
 eGFR (mL/min/1.73 m2) | 35.6 ± 10.9 | 29.1 ± 7.2 | 26.0 ± 10.0 |  |
 ΔeGFR (mL/min/1.73 m2/yr) | −6.6 ± 5.7 |  | −3.1 ± 5.6 | 0.465 |